ELHT Evidence Hub
  • Home
  • Meet the Team
  • Library Facilities
  • Library News
  • FAQS
  • Evidence Search Request
Picture

A Randomized, Double-Blind, Biomarker- Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma

30/8/2022

0 Comments

 
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Aug 12, pp. JCO2200405. Date of Electronic Publication: 2022 Aug 12.
Publication Model: Ahead of Print
Abstract:
Purpose: A DNA repair deficiency (DRD) phenotype exists within a subset of metastatic urothelial carcinomas (mUC) predicting benefit from platinum-based chemotherapy. We tested switch maintenance therapy with the poly ADP-ribose polymerase inhibitor rucaparib, following chemotherapy, for DRD biomarker-positive mUC.
Methods: DRD biomarker-positive mUC patients, within 10 weeks of chemotherapy, and without cancer progression, were randomly assigned (1:1) to maintenance rucaparib 600 mg twice a day orally, or placebo, until disease progression. The primary end point was progression-free survival (PFS). Statistical analysis targeted a hazard ratio of 0.5 with a 20% one-sided α for this signal-seeking trial. PFS (RECIST 1.1) was compared between trial arms, by intention to treat, within a Cox model.
Results: Out of 248 patients, 74 (29.8%) were DRD biomarker-positive and 40 were randomly assigned. A total of 12 (60%) and 20 (100%) PFS events occurred in the rucaparib and placebo arms, respectively (median follow-up was 94.6 weeks in those still alive). Median PFS was 35.3 weeks (80% CI, 11.7 to 35.6) with rucaparib and 15.1 weeks (80% CI, 11.9 to 22.6) with placebo (hazard ratio, 0.53; 80% CI, 0.30 to 0.92; one-sided P = .07). In the safety population (n = 39) treatment-related adverse events were mostly low grade. Patients received a median duration of 10 rucaparib or six placebo cycles on treatment. Treatment-related adverse events (all grades) of fatigue (63.2% v 30.0%), nausea (36.8% v 5.0%), rash (21.1% v 0%), and raised alanine aminotransferase (57.9% v 10%) were more common with rucaparib.
Conclusion: Maintenance rucaparib, following platinum-based chemotherapy, extended PFS in DRD biomarker-selected patients with mUC and was tolerable. Further investigation of poly ADP-ribose polymerase inhibition in selected patients with mUC is warranted.

Full text available here 

0 Comments



Leave a Reply.

    The following databases were searched:
    EMBASE,  MEDLINE, PsycINFO, BNI, CINAHL, 
    to find  ELHT staff publications

    Specialties

    All
    ANAESTHETICS
    CAMHS
    CARDIOLOGY
    COVID 19
    DEMENTIA
    DERMATOLOGY
    DIABETES
    DIETETICS
    EMERGENCY CARE
    ENDOCRINOLOGY
    EVIDENCE BASED MEDICINE
    GASTROENTEROLOGY
    GYNAECOLOGY
    HAEMATOLOGY
    MATERNITY
    MAXILLOFACIAL
    NEONATOLOGY
    NEUROLOGY
    NURSING
    OBSTETRICS
    ONCOLOGY
    ORTHOPAEDICS
    PAEDIATRICS
    PHARMACY
    PHYSIOTHERAPY
    RADIOLOGY
    RESPIRATORY
    RHEUMATOLOGY
    STROKE
    SURGERY
    UROLOGY
    VASCULAR SURGERY

    RSS Feed

    Archives

    August 2022
    July 2022
    May 2022
    April 2022
    March 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    December 2020
    November 2020
    October 2020
    September 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019

Learning Centre Library
Royal Blackburn Teaching Hospital
01254 734312 or Ext 84312
library.blackburn@elht.nhs.uk
​Find us
​​Mackenzie Library
Burnley General Teaching Hospital
01282 803114 or Ext. 13114
library.burnley@elht.nhs.uk

Find us
​Staffed Opening Hours
Mon     08:30-16:30
Tue      08:30-16:30
Wed     08:30-16:30
Thu      08:30-16:30
Fri        08:30-16:00
24/7 access to both libraries is available - please see library staff
View our Quality Standards and Performance
Picture
Picture
  • Home
  • Meet the Team
  • Library Facilities
  • Library News
  • FAQS
  • Evidence Search Request